These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 34919824)

  • 1. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS
    Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
    N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotorasib for Lung Cancers with
    Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
    N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
    de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
    Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated
    Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
    N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotorasib in
    Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS
    N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotorasib with panitumumab in chemotherapy-refractory KRAS
    Kuboki Y; Fakih M; Strickler J; Yaeger R; Masuishi T; Kim EJ; Bestvina CM; Kopetz S; Falchook GS; Langer C; Krauss J; Puri S; Cardona P; Chan E; Varrieur T; Mukundan L; Anderson A; Tran Q; Hong DS
    Nat Med; 2024 Jan; 30(1):265-270. PubMed ID: 38177853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS
    Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC
    J Thorac Oncol; 2024 Jul; 19(7):995-1006. PubMed ID: 38615940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
    Hochmair MJ; Vermaelen K; Mountzios G; Carcereny E; Dooms C; Lee SH; Morocz E; Kato T; Ciuleanu TE; Dy GK; Parente B; O'Byrne KJ; Chu QS; Castro Junior G; Girard N; Snyder W; Tran Q; Kormany W; Houk B; Mehta B; Curioni-Fontecedro A
    Eur J Cancer; 2024 Sep; 208():114204. PubMed ID: 39029295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
    Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
    JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Garsorasib in patients with KRAS
    Li Z; Dang X; Huang D; Jin S; Li W; Shi J; Wang X; Zhang Y; Song Z; Zhang J; Zhuang W; Liu X; Jiang L; Meng X; Zhao M; Zhou J; Zhang L; Wang P; Luo H; Yang J; Cang S; Wang X; Zhang L; Lu S;
    Lancet Respir Med; 2024 Aug; 12(8):589-598. PubMed ID: 38870979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
    Waterhouse DM; Rothschild S; Dooms C; Mennecier B; Bozorgmehr F; Majem M; van den Heuvel MH; Linardou H; Chul Cho B; Roberts-Thomson R; Tanaka K; Blais N; Schvartsman G; Holmskov Hansen K; Chmielewska I; Forster MD; Giannopoulou C; Stollenwerk B; Obiozor CC; Wang Y; Novello S
    Lung Cancer; 2024 Oct; 196():107921. PubMed ID: 39303400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired Resistance to KRAS
    Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
    N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.